Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PainCart study of SAGE-319 analgesic profile
NL-OMON59227Phase 1Completed
- Sponsor
- Sage Therapeutics
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of SAGE-319 in pain and disorders of gamma-aminobutyric acid signaling and cerebellar circuitry, sponsored by Sage Therapeutics. Started Jun 2025; status: completed.
02
Drugs
SAGE-319
03
Conditions
paindisorders of gamma-aminobutyric acid signaling and cerebellar circuitry
Beyond the preview
Go deeper on NL-OMON59227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59227.